


**PRODUCT: EML-425****ALTERNATE NAME:** 5-[(4-Hydroxy-2,6-dimethylphenyl)methylene]-1,3-bis(phenylmethyl)-2,4,6-(1H,3H,5H)-pyrimidinetrione**CATALOG NUMBER:** B1882-5,25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C<sub>27</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>**MOLECULAR WEIGHT:** 440.49**CAS NUMBER:** 1675821-32-5**APPEARANCE:** Yellow solid**SOLUBILITY:** DMSO (>40 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from air and light**DESCRIPTION:**

EML-425 is a potent, reversible and non-competitive dual CBP and p300 inhibitor (IC<sub>50</sub> values are 1.1 and 2.9 μM, respectively). EML425 induced a marked and time-dependent reduction in the acetylation of lysine H4K5 and H3K9, a marked arrest in the G0/G1 phase and a significant increase in the hypodiploid nuclei percentage in human leukemia U937 cells. Cell-permeable.

**REFERENCES:** Zhou, Z., et al. (2014). *PLoS One*. Jan 10;9(1):e85406. doi: 10.1371/journal.pone.0085406**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

A-366 (Cat. No. 2859-1, 5)

AMI-1 (Cat. No. 1943-5, 25)

Aza-2'-deoxycytidine (Cat. No. 1754-10, 50)

BAZ2-ICR (B1865)

BI-7273 (B1879)

BI-9564 (B1880)

5- BIX01294 (Cat. No. 1678-5, 25)

Bromodomain Inhibitor, (+)-JQ1 (Cat. No. 2070-1, 5)

BRD4770 (Cat. No.9525-5, 25)

EZSolution™ (+)-JQ1 (Cat. No. 2091-1)

3-Deazaneplanocin (Cat. No. 2060-250, 1000)

2'-Deoxy-5-fluorocytidine (Cat. No. 2387-50, 250)

EML-425 (Cat. No. B1882-5,25)

EPZ-015666 (Cat. No. 9510-1,5)

EPZ011989 (Cat. No. B1221-5,25)

Lomeguatrib (Cat. No. 2224-5, 25)

Mivebresib (Cat. No. B1564-5,25)

Nanaomycin A (Cat. No. 2790-5, 25)

RG108 (Cat. No. 1679-10, 30)

SGI-1027 (Cat. No. 2726-5, 25)

UNC0638 (Cat. No. 1933-1, 5)

UNC0642 (Cat. No. 2862-5, 25)

Zebularine (Cat. No. 2225-1,

**USAGE:** **FOR RESEARCH USE ONLY! Not to be used in humans**